Once‐daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double‐blind, randomized, paroxetine‐controlled, non‐inferiority trial in China, Korea, Taiwan and Brazil
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The aim of the present paper was to compare the efficacy and safety of duloxetine with paroxetine in the acute treatment of major depressive disorder (MDD). In a randomized, double‐blind trial of 8 weeks active treatment, patients with non‐psychotic MDD were randomized to duloxetine 60 mg (n = 238) or paroxetine 20 mg (n = 240) once daily. Efficacy was primarily measured on change in the 17‐item Hamilton Rating Scale for Depression (HAMD 17) using a non‐inferiority test with a margin of 2.2. Secondary efficacy measures included the HAMD 17 subscales, Hamilton Rating Scale for Anxiety, Clinical Global Impressions–Severity, Patient Global Impressions–Improvement, Somatic Symptoms Inventory and Visual Analog Scales (VAS) for pain. Safety measures included treatment‐emergent adverse events (TEAE), vital signs, weight, laboratory analyses and electrocardiograms. Non‐inferiority of duloxetine to paroxetine was demonstrated because the upper bound of the confidence interval for mean difference in HAMD 17 change (0.71) was less than the non‐inferiority margin. Secondary efficacy end‐points did not differ significantly between treatments with the exception of VAS back pain, where the pooled mean was lower in the duloxetine group (17.1) compared with the paroxetine group (20.3, P = 0.048). No significant differences were observed in the number of early discontinuations and overall TEAE. However, significantly greater proportions of patients in the duloxetine group experienced nausea and palpitations. No clinically relevant changes in laboratory values, vital signs, weight or electrocardiograms were observed with either treatment. The present study verifies the utility of duloxetine as an efficacious and safe treatment for both emotional and physical symptoms of MDD in this predominantly Asian patient sample.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
An international study of the relation between somatic symptoms and depression
Simon, G. E., VonKorff, M., Piccinelli, M., Fullerton, C., & Ormel, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411801 · Cited by 1,303 · cited 1×
“As with any medication, the possibility thus exists that duloxetine will have a different efficacy and/or tolerability profile in other ethnic or cultural settings where differences in the presentation of the disease and clinical practices may exist.(2) The objective of the present study was to compare the efficacy an…”
BackgroundReporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153
Anderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940 · cited 1×
“Although SNRI have been shown to have advantages in terms of tolerability and safety compared with the older TCA,(6,36) previous studies have indicated that there is little, if any, difference between antidepressants, including the TCA and newer classes such as the SSRI and SNRI, in efficacy on traditional emotional s…”
ResultArnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471 · cited 1×
“In further support of duloxetine’s analgesic properties, it has been shown to be effective in nondepressed patients, for example in diabetic neuropathic pain(40) and fibromyalgia.(41) The results from the current study for the VAS pain measures are therefore noteworthy, with duloxetine having numerical advantages in p…”
ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS
Mallinckrodt, C. H., Clark, W. S., & David, S. R. (2001) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-100104194 · Cited by 398 · cited 1×
“The average treatment effects over the entire study period were assessed using a restricted maximum likelihood (REML)-based, mixed-effects model, repeated-measures approach (MMRM).(32) Models included terms for the baseline score, treatment, center, visit, and treatment ¥ visit interaction and baseline score ¥ visit i…”
MethodDetke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384 · cited 4×
“However, it has been proposed that duloxetine (as well as other antidepressants with dual activity), due to its effect on NE and 5-HT re-uptake activity, may have improved efficacy in some painful physical symptoms associated with depression.(15,21,33) When compared with placebo, previous studies have demonstrated the…”
BackgroundResultInfluentialImpact of pain on depression treatment response in primary care
Bair, M. J., Robinson, R. L., Eckert, G. J., Stang, P. E., Croghan, T. W., & Kroenke, K. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000106883.94059.c5 · Cited by 371
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334
Cited by
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Mohr, D. C., Ho, J., Duffecy, J., Reifler, D., Sokol, L., Burns, M. N., Jin, L., & Siddique, J. (2012) · JAMA · doi:10.1001/jama.2012.5588 · Cited by 330
A systematic review of duloxetine and venlafaxine in major depression, including unpublished data
Schueler, Y. ‐., Koesters, M., Wieseler, B., Grouven, U., Kromp, M., Kerekes, M. F., Kreis, J., Kaiser, T., Becker, T., & Weinmann, S. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01599.x · Cited by 87
Alexopoulos, G. S., Raue, P. J., Banerjee, S., Marino, P., Renn, B. N., Solomonov, N., Adeagbo, A., Sirey, J. A., Hull, T. D., Kiosses, D. N., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0832-3 · Cited by 56
Metadata
- Authors
- LEE, P., SHU, L., XU, X., WANG, C. Y., LEE, M. S., LIU, C., HONG, J. P., RUSCHEL, S., RASKIN, J., COLMAN, S. A., & HARRISON, G. A.
- Venue
- Psychiatry and Clinical Neurosciences
- Publisher
- Wiley
- Published
- 2007-04-28
- Volume
- 61
- Issue
- 3
- Pages
- 295-307
- ISSN
- 1323-1316 (ISSN-L)
- 1440-1819
- OpenAlex
- W2098354008
- Cited by
- 50
- References
- 9
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Once‐daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double‐blind, randomized, paroxetine‐controlled, non‐inferiority trial in China, Korea, Taiwan and Brazil. https://app.cochat.ai/papers/10.1111/j.1440-1819.2007.01666.x
- The paper
- LEE, P., SHU, L., XU, X., WANG, C. Y., LEE, M. S., LIU, C., HONG, J. P., RUSCHEL, S., RASKIN, J., COLMAN, S. A., & HARRISON, G. A. (2007). Once‐daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double‐blind, randomized, paroxetine‐controlled, non‐inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.2007.01666.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.